Literature DB >> 3841420

Turnover study of heparin cofactor II in healthy man.

P Sié, D Dupouy, J Pichon, B Boneu.   

Abstract

Heparin cofactor II (HC II) is a heparin-dependent inhibitor of thrombin, distinct from antithrombin III (AT III). This study was designed to evaluate its metabolism in healthy subjects. Purified HC II was labelled with 125I by the lactoperoxidase-glucose oxidase technique. The biological activity of the HC II was unchanged after labelling as was its migratory pattern by crossed immunoelectrophoresis in the presence of heparin or dermatan sulfate. Three healthy volunteers were injected with 10 microCi and the plasma radioactivity was measured daily. The data were approximated by a sum of two exponential terms and the metabolism of HC II was described by a two compartment mamillary system. The mean values of fractional catabolic rate, intravascular fraction and half-life of the elimination phase were respectively: 0.44 d-1, 0.60 and 2.53 d. These parameters are of the same order of magnitude as those reported in the literature for AT III. The plasma HC II concentration in the 3 subjects ranged from 61 to 82 micrograms/ml as estimated using our purified preparation. Accordingly, the absolute catabolic rate ranged from 1.17 to 1.36 mg X kg-1 X d-1.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3841420

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

1.  Heparin cofactor II inhibits arterial thrombosis after endothelial injury.

Authors:  Li He; Cristina P Vicente; Randal J Westrick; Daniel T Eitzman; Douglas M Tollefsen
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

Review 2.  Revisiting the Pharmacology of Unfractionated Heparin.

Authors:  Abdallah Derbalah; Stephen Duffull; Fiona Newall; Katie Moynihan; Hesham Al-Sallami
Journal:  Clin Pharmacokinet       Date:  2019-08       Impact factor: 6.447

3.  Accelerated atherogenesis and neointima formation in heparin cofactor II deficient mice.

Authors:  Cristina P Vicente; Li He; Douglas M Tollefsen
Journal:  Blood       Date:  2007-09-18       Impact factor: 22.113

4.  Vascular dermatan sulfate regulates the antithrombotic activity of heparin cofactor II.

Authors:  Li He; Tusar K Giri; Cristina P Vicente; Douglas M Tollefsen
Journal:  Blood       Date:  2008-02-15       Impact factor: 22.113

5.  Non-enzymatic glycation reduces heparin cofactor II anti-thrombin activity.

Authors:  A Ceriello; E Marchi; M Barbanti; M R Milani; D Giugliano; A Quatraro; P Lefebvre
Journal:  Diabetologia       Date:  1990-04       Impact factor: 10.122

Review 6.  Anticoagulant SERPINs: Endogenous Regulators of Hemostasis and Thrombosis.

Authors:  Steven P Grover; Nigel Mackman
Journal:  Front Cardiovasc Med       Date:  2022-05-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.